Works Cited

1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978.

2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537-544.

3. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17(1):39-57.

4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision. Arlington, VA: American Psychiatric Association; 2022.

5. Parish SH, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437-447.

6. Giraldi A, Rellini AH, Pfaus J, Laan E. Female sexual arousal disorders. J Sex Med. 2013;10(1):58-73.

7. Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy. 2012;32(1):38-53.

8. Kingsberg SA, Woodard T. Female sexual dysfunction: focus on low desire. Obstet Gynecol. 2015;125(2):477-486.

9. Angel K. Contested psychiatric ontology and feminist critique: "female sexual dysfunction" and the Diagnostic and Statistical Manual. Hist Human Sci. 2012;25(4):3-24.

10. Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014;11(6):1392-1422.

11. Jannini EA, Isidori AM, Aversa A, Lenzi A. Althof SE. Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. J Sex Med. 2013;10(10):2359-2369.

12. Mercer CH. Sexual behaviour. Medicine (Abingdon). 2014;42(6):291-293.

13. Marnash ML, Casey PM. Understanding women's sexual health: a case-based approach. Mayo Clin Proc. 2008;83(12):1382-1387.

14. Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Exp Opin Pharmacotherapy. 2015;16(6):875-887.

15. Basson R. Human sex-response cycles. J Sex Marital Ther. 2001;27(1):33-43.

16. Basson R. A model of women's sexual arousal. J Sex Marital Ther. 2002;28(1):1-10.

17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Arlington, VA: American Psychiatric Association; 2000.

18. Poels S, Bloemers J, van Rooij K, Kopperschaar H, Olivier B, Tuiten A. Two novel combined drug treatments for women with hypoactive sexual desire disorder. Pharmacol Biochem Behav. 2014;121:71-79.

19. Lamont J, Bajzak K, Bouchard C, et al. No. 279-female sexual health consensus clinical guidelines. J Obstet Gynaecol Can. 2018;40(6):e451-e503.

20. Meston CM, Hull E, Levin RJ, Sipski M. Disorders of orgasm in women. J Sex Med. 2004;1(1):66-68.

21. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal. An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510.

22. Meston CM, Buss DM. Why humans have sex. Arch Sex Behav. 2007;36(4):477-507.

23. Seehusen DA, Baird DC, Bode DV. Dyspareunia in women. Am Fam Physician. 2014;90(7):465-470.

24. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014;78(2):91-98.

25. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal Changes) survey. J Sex Med. 2013;10(7):1790-1799.

26. Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226-232.

27. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208.

28. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress for women. J Sex Marital Ther. 2002;28(4):317-330.

29. Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7 (4 Pt 2):1598-1607.

30. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of U.S. women. Arch Intern Med. 2008;168(13):1441-1449.

31. Harlow BL, Wise LA, Stewart EG. Prevalence and predictors of chronic lower genital discomfort. Am J Obstet Gynecol. 2001;185(3):545-550.

32. Goetsch M. Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. Am J Obstet Gynecol. 1991;164(6 Pt 1):1609-1614.

33. Arnold LD, Bachmann GA, Rosen R, Rhoads GG. Assessment of vulvodynia symptoms in a sample of U.S. women: a prevalence survey with a nested case control study. Am J Obstet Gynecol. 2007;196(2):128.e1-6.

34. Rosen RC, Connor MK, Maserejian NN. The HSDD registry for women: a novel patient registry for women with generalized acquired hypoactive sexual desire disorder. J Sex Med. 2010;7(5):1747-1756.

35. Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet. 2007;369(9561):597-611.

36. Atis G, Dalkilinc A, Altuntas Y, et al. Hyperthyroidism: a risk factor for female sexual dysfunction. J Sex Med. 2011;8(8):2327-2333.

37. Gulmez H, Akin Y, Savas M, et al. Impact of iron supplementation on sexual dysfunction of women with iron deficiency anemia in short term: a preliminary study. J Sex Med. 2014;11(4):1042-1046.

38. Hallikas J, Weller R, Morse C. Effects of regular marijuana on sexual performance. J Psychoactive Drugs. 1982;14(1-2):59-70.

39. Kasman AM, Bhambhvani HP, Wilson-King G, Eisenberg ML. Assessment of the association of cannabis on female sexual function with the Female Sexual Function Index. Sex Med. 2020;8(4):699-708.

40. Palha A, Esteves M. A study of the sexuality of opiate addicts. J Sex Marital Ther. 2002;28(5):427-437.

41. Farnia V, Shakeri J, Tatari F, AhmadiJuibari T, Yazdchi K, Abdoli N. The evaluation of sexual dysfunction among male patients with methamphetamine abuse and withdrawal. J Subst Use. 2015;20(5):363-366.

42. Henderson D, Boyd CJ, Whitmarsh J. Women and illicit drugs: sexuality and crack cocaine. Health Care Women Int. 1995;16(2):113-124.

43. Lorvick J, Bourgois P, Wenger LD, et al. Sexual pleasure and sexual risk among women who use methamphetamine: a mixed methods study. Int J Drug Policy. 2013;23(5):385-392.

44. Derogatis LR, Psychiatric Times. Female Sexual Dysfunction. What We Know, What We Suspect, and Enduring Enigmas. Available at https://www.psychiatrictimes.com/articles/female-sexual-dysfunctionwhat-we-know-what-we-suspect-and-enduring-enigmas. Last accessed November 15, 2022.

45. Harte CB, Meston CM. The inhibitory effects of nicotine on physiological sexual arousal in nonsmoking women: results from a randomized, double-blind, placebo-controlled, cross-over trial. J Sex Med. 2008;5(5):1184-1197.

46. Wouters H, Van Dijk L, Van Geffen EC, Gardarsdottir H, Stiggelbout AM, Bouvy ML. Primary-care patients' trade-off preferences with regard to antidepressants. Psychol Med. 2014;44(11):2301-2308.

47. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-266.

48. Ali SK, Reveles KR, Davis R, Mortensen EM, Frei CR, Mansi I. The association of statin use and gonado-sexual function in women: a retrospective cohort analysis. J Sex Med. 2015;12(1):83-92.

49. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15(4 Pt 1):661-666.

50. Dennerstein L, Lehert P, Burger H, Dudley E. Factors affecting sexual functioning of women in the mid-life years. Climacteric. 1999;2(4):254-262.

51. von Hippel C, Adhia A, Rosenberg S, Austin SB, Partridge A, Tamimi R. Sexual function among women in midlife: findings from the Nurses' Health Study II. Womens Health Issues. 2019;29(4):291-298.

52. Fisher WA, Byrne D, White LA, Kelley K. Erotophobia-erotophilia as a dimension of personality. J Sex Res. 1988;25(1):123-151.

53. Weaver AD, Byers ES. The relationships among body image, body mass index, exercise and sexual functioning in heterosexual women. Psychol Women Q. 2006;30(4):333-339.

54. de Lucena BB, Abdo CHN. Personal factors that contribute to or impair women's ability to achieve orgasm. Int J Impot Res. 2014;26(5):177-181.

55. Afari N, Ahumada SM, Wright LJ, et al. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. Psychosom Med. 2014;76(1):2-11.

56. Cichowski SB, Dunivan GC, Komesu YM, et al. Sexual abuse history and pelvic floor disorders in women. South Med J. 2013;106(12):675-678.

57. Stephenson KR, Hughan CP, Meston CM. Childhood sexual abuse moderates the association between sexual functioning and sexual distress in women. Child Abuse Negl. 2012;36(2):180-189.

58. Schloredt K, Heiman J. Perceptions of sexuality as related to sexual functioning and sexual risk in women with different types of childhood abuse histories. J Trauma Stress. 2003;16(3):275-284.

59. Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013;202(6):396-397.

60. Williams K, Reynolds MF. Sexual dysfunction in major depression. CNS Spectr. 2006;11(Suppl 9):19-23.

61. Leonard LM, Follette VM. Sexual functioning in women reporting a history of child sexual abuse: clinical and empirical considerations. Annu Rev Sex Res. 2002;13:346-388.

62. Najman JM, Dunne MP, Purdie DM, Boyle FM, Coexter PD. Sexual abuse in childhood and sexual dysfunction in adulthood: an Australian population-based study. Arch Sex Behav. 2005;34(5):517-526.

63. Barlow DH. Causes of sexual dysfunction: the role of cognitive interference. J Consult Clin Psychol. 1986;54(2):140-148.

64. Elliott AN, O'Donahue WT. The effects of anxiety and distraction on sexual arousal in a nonclinical sample of heterosexual women. Arch Sex Behav. 1997;26(6):607-624.

65. Purdon C, Holdaway L. Non-erotic thoughts: content and relation to sexual functioning and sexual satisfaction. J Sex Res. 2006;43(2):154-162.

66. Pujols Y, Seal BN, Meston CM. The association between sexual satisfaction and body image in women. J Sex Med. 2010;7 (2 Pt 2):905-916.

67. Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M. Women's sexual desire and arousal disorders. J Sex Med. 2010;7(1 Pt 2):586-614.

68. Lawrence K, Byers ES. Sexual satisfaction in long-term heterosexual relationship: the interpersonal exchange model of sexual satisfaction. Pers Relatsh. 1995;2(4):267-285.

69. Basson R. Female sexual response: the role of drugs in the management of sexual dysfunction. Obstet Gynecol. 2001;98(2):350-353.

70. MacNeil S, Byers ES. Dyadic assessment of sexual self-disclosure and sexual satisfaction in heterosexual dating couples. J Soc Pers Relat. 2005;22(2):169-181.

71. MacNeil S, Byers ES. Role of sexual self-disclosure in the sexual satisfaction of long-term heterosexual couples. J Sex Res. 2009;46(1):1-12.

72. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA)—results from an international survey. Climacteric. 2012;15(1):36-44.

73. Goldstein I, Dicks B, Kim NN, et al. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in post-menopausal women. Sex Med. 2013;1(2):44-53.

74. Gordon D, Gardella C, Eschenbach D, Mitchell CM. High prevalence of sexual dysfunction in a vulvovaginal specialty clinic.J Low Genit Tract Dis. 2016;20(1):80-84.

75. Burrows LJ, Klingman D, Pukall CF, Goldstein AT. Umbilical hypersensitivity in women with primary vestibulodynia. J Reprod Med. 2008;53(6):413-416.

76. Farmer MA, Meston CM. Predictors of genital pain in young women. Arch Sex Behav. 2007;36(6):831-843.

77. Bouchard C, Brisson J, Fortier M, Morin C, Blanchette C. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. Am J Epidemiol. 2002;156(3):254-261.

78. Greenstein A, Ben-Aroya Z, Fass O, et al. Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills. J Sex Med. 2007;4(6):1679-1683.

79. Bohm-Starke N, Johannesson U, Hilliges M, Rylander E, Torebjörk E. Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: a contributing factor in vulvar vestibulitis? J Reprod Med. 2004;49(11):888-892.

80. Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. Sex Med. 2013;1(1):30-33.

81. Edgardh K, Abdelnoor M. Vulvar vestibulitis and risk factors: a population-based case-control study in Oslo. Acta Derm Venereol. 2007;87(4):350-354.

82. Lee M, Morgan M, Rapkin A. Clitoral and vulvar vestibular sensation in women taking 20 mcg ethinyl estradiol combined oral contraceptives: a preliminary study. J Sex Med. 2011;8(1):213-218.

83. Watts G, Nettle D. The role of anxiety in vaginismus: a case-control study. J Sex Med. 2010;7(1 Pt 1):143-148.

84. North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902.

85. Althof SE, Rosen RC, Perelman MA, Rubio-Aurioles E. Standard operating procedures for taking a sexual history. J Sex Med. 2013;10(1):26-35.

86. Bitzer J, Giraldi A, Pfaus J. A standardized diagnostic interview for hypoactive sexual desire disorder in women: standard operating procedure (SOP Pt 2). J Sex Med. 2013;10(1):50-57.

87. Arnold LD, Bachmann GA, Rosen R, Kelly S, Rhoads GG. Vulvodynia: characteristics and associations with comorbidities and quality of life. Obstet Gynecol. 2006;107(3):617-624.

88. Plante AF, Kamm MA. Life events in patients with vulvodynia. BJOG. 2008;115(4):509-514.

89. Lamont JA. Vaginismus. Am J Obstet Gynecol. 1978;131(6):633-636.

90. Steege JF, Zolnoun DA. Evaluation and treatment of dyspareunia. Obstet Gynecol. 2009;113(5):1124-1136.

91. Wylie K. Assessment and management of sexual problems in women. J R Soc Med. 2007;100(12):547-550.

92. Nappi R, Salonia A, Traish AM, et al. Clinical biologic pathophysiologies of women's sexual dysfunction. J Sex Med. 2005;2(1): 4-25.

93. Berman JR. Physiology of female sexual function and dysfunction. Int J Impot Res. 2005;17(Suppl 1):S44-S51.

94. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord. 1999;56(2-3):201-208.

95. Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. CNS Spectr. 2006;11(8 Suppl 9):24-30.

96. Doumas M, Tsiodras S, Tsakiris A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24(12):2387-2392.

97. Binik YM, Hall KSK (eds). Principles and Practice of Sexual Therapy. 5th ed. New York, NY: Guilford Press; 2014.

98. Althof S. Sexual therapy in the age of pharmacotherapy. Ann Rev Sex Res. 2006;17(1):116-132.

99. Althof S. When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res. 2002;14(Suppl 1): S99-S104.

100. Bradford A. Inhibited sexual desire in women. In: Grossman LR, Walfish S, (eds). Translating Psychological Research into Practice. New York, NY: Springer; 2014: 515-518.

101. Frühauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav. 2013;42(6):915-933.

102. Günzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions—a systematic review of controlled clinical trials: part 2—the efficacy of psychosocial interventions for female sexual dysfunction. J Sex Med. 2012;9(12):3108-3125.

103. Reis SLB, Abdo CHN. Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors. Clinics. 2014;69(4):294-303.

104. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves First Treatment for Sexual Desire Disorder. Available at https://wayback.archive-it.org/7993/20170112023753/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm458734.htm. Last accessed November 15, 2022.

105. BioSpace. Sprout Pharmaceuticals Resubmits Flibanserin New Drug Application For The Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women. Available at https://www.biospace.com/article/releases/sprout-pharmaceuticals-resubmits-flibanserin-new-drug-application-for-the-treatment-of-hypoactive-sexual-desire-disorder-in-premenopausal-women-/. Last accessed November 15, 2022.

106. U.S. Food and Drug Administration. FDA Approves New Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women. Last accessed November 15, 2022.

107. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause. 2006;13(5):737-743.

108. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92(4 Pt 2):722-727.

109. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 2013;20(2):162-168.

110. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931-6940.

111. Whelan TJ, Pritchard KI. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res. 2006;12(3 Pt 2):1056s-1060s.

112. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11(2):487-497.

113. Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman D, Ylikorkala O. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173-182.

114. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med. 2006;166(14):1483-1489.

115. van Staa T, Sprafka, J. Study of adverse outcomes in women using testosterone therapy. Maturitas. 2009;62(1):76-80.

116. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011;27(1):39-48.

117. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in post-menopausal women. J Sex Med. 2012;9(4):1134-1148.

118. Davis SR. Cardiovascular and cancer safety of testosterone in women. Curr Opin Endocrinol Diabetes Obes. 2011;18(3):198-203.

119. Dahir M, Travers-Gustafson D. Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy. Sex Med. 2014;2(1):8-15.

120. Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist. 2011;16(4):424-431.

121. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in post-menopausal women. J Sex Med. 2010;7(3):1284-1290.

122. Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313-319.

123. Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric. 2011;14(6):661-668.

124. Bloch M, Meiboom H, Zaig I, Schreiber S, Abramov L. The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. Eur Neuropsychopharmacol. 2013;23(8):910-918.

125. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(5):923-931.

126. Labrie F, Archer D, Bouchard C, et al. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med. 2014;11(7):1766-1785.

127. Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric. 2015;18(2):219-225.

128. Zolnoun D, Hartmann KE, Steege JF. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol. 2003;102(1):84-87.

129. Goldstein A. Surgical techniques: surgery for vulvar vestibulitis syndrome. J Sex Med. 2006;3(3):559-562.

130. Goldstein AT, Klingman D, Christopher K, Johnson C, Marainoff SC. Surgical treatment of vulvar vestibulitis syndrome: outcome assessment derived from a postoperative questionnaire. J Sex Med. 2006;3(5):923-931.

131. Zoorob D, South M, Karram M, et al. A pilot randomized trial of levator injections versus physical therapy for treatment of pelvic floor myalgia and sexual pain. Int Urogynecol. 2015;26(6):845-852.

132. Dmitrovic R, Kunselman AR, Legro RS. Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial. Hum Reprod. 2013;28(11):2958-2965.

133. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8(1):15-27.

134. Joffe HV, Chang C, Sewell C, et al. FDA approval of flibanserin: treating hypoactive sexual desire disorder. N Engl J Med. 2016;374(2):101-104.

135. LexiComp Online. Available at https://online.lexi.com. Last accessed November 15, 2022.

136. Segraves RT, Croft H, Kavoussi R, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther. 2001;27(3):303-316.

137. Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106(6):832-839.

138. Liao Q, Zhang M, Geng L, et al. Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study in Chinese population. J Sex Med. 2008;5(8):1923-1931.

139. Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Cianci A. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology. 2004;63(5):955-959.

140. Bechara A, Bertolino MV, Casabé A, et al. A double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine. J Sex Med. 2004;1(2):209-214.

141. Fabre LF, Brown CS, Smith LC, Derogatis LR. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. J Sex Med. 2011;8(5):1411-1419.

142. Poels S, Bloemers J, van Rooij K, et al. Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. J Sex Med. 2013;10(3):810-823.

143. Bottari A, Belcaro G, Ledda A, Luzzi R, Cesarone MR, Dugall M. Lady Prelox® improves sexual function in generally healthy women of reproductive age.Minerva Ginecol. 2013;65(4):435-444.

144. Meston CM, Rellini AH, Telch MJ. Short- and long-term effects of Ginkgo biloba extract on sexual dysfunction in women. Arch Sex Behav. 2008;37(4):530-547.

145. Pebdani MA, Taavoni S, Seyedfatemi N, Haghani H. Triple-blind placebo-controlled trial of ginkgo biloba extract on sexual desire in postmenopausal women in Tehran. Iran J Nurs Midwifery Res. 2014;19(3):262-265.

146. Roman P, Ortiz-Rodriguez A, Romero-Lopez A, et al. The influence of cannabis and alcohol use on sexuality: an observational study in young people (18-30 years). Healthcare (Basel). 2021;10(1):71.

147. Lynn BK, López JD, Miller C, Thompson J, Campian EC. The relationship between marijuana use prior to sex and sexual function in women. Sex Med. 2019;7(2):192-197.

Evidence-Based Practice Recommendations Citations

1. American College of Obstetricians and Gynecologists. Female sexual dysfunction: ACOG Practice Bulletin summary, number 213.Obstet Gynecol. 2019;134(1):203-205. Available at https://journals.lww.com/greenjournal/Abstract/2019/07000/Female_Sexual_Dysfunction__ACOG_Practice_Bulletin.42.aspx. Last accessed November 21, 2022.


Copyright © 2022 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.